AbbVie has a strong presence in immunology, oncology and neuroscience areas. Other than that, AbbVie also has products for ...

Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two ...

Pfizer's coronavirus vaccine could face some headwinds in the near future. The company will enter a period of patent cliffs ...

Pfizer’s PFE top line has been declining in 2023 due to a steep drop in revenues from its COVID-19 products, the Comirnaty vaccine and Paxlovid oral pill, on lower demand due to the end of the ...

May 2 (Reuters) - Pfizer Inc (PFE.N), opens new tab on Tuesday reported higher-than-expected first-quarter revenue and profit, buoyed by demand for its COVID-19 products, and reaffirmed its 2023 ...

Drug giant Pfizer is informing hospitals that dozens of its products could face “continued or new supply disruptions in the near-term” after an EF-3 tornado last week severely damaged its plant in ...

Pfizer on Tuesday reported its first quarterly loss since 2019 as demand for its COVID products dwindled. Sales of the company's coronavirus vaccine Comirnaty dropped 70% during the third quarter ...

Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts.Q3 Earnings ...

Pfizer reported a record $100 billion in annual revenue in 2022 due to the development of Comirnaty and Paxlovid. COVID treatments no longer boost sales, causing the stock to trade near a ten-year low ...

Pfizer's strategy that will help it rebound from recent struggles is in full motion. It says a lot that the company continues ...

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures, and markets medicines, ...